Secreted phospholipase A2 type IIA (sPLA2-IIA) activates integrins in an allosteric manner

Yoshikazu Takada, Masaaki Fujita

Research output: Chapter in Book/Report/Conference proceedingChapter

3 Citations (Scopus)

Abstract

Secreted phospholipase A2 type IIA (sPLA2-IIA) is a well-established pro-inflammatory protein and has been a major target for drug discovery. However, the mechanism of its signaling action has not been fully understood. We previously found that sPLA2-IIA binds to integrins αvβ3 and α4β1 in human and that this interaction plays a role in sPLA2-IIA’s signaling action. Our recent studies found that sPLA2-IIA activates integrins in an allosteric manner through direct binding to a newly identified binding site of integrins (site 2), which is distinct from the classical RGD-binding site (site 1). The sPLA2-IIA-induced integrin activation may be related to the signaling action of sPLA2-IIA. Since sPLA2-IIA is present in normal human tears in addition to rheumatoid synovial fluid at high concentrations the sPLA2-IIA-mediated integrin activation on leukocytes may be involved in immune responses in normal and pathological conditions.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages103-115
Number of pages13
Volume925
DOIs
Publication statusPublished - 2017

Publication series

NameAdvances in Experimental Medicine and Biology
Volume925
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Fingerprint

Secretory Phospholipase A2
Integrins
Chemical activation
Binding Sites
Synovial Fluid
Drug Discovery
Tears
Leukocytes
Fluids

Keywords

  • Allosteric site
  • Docking simulation
  • Integrin activation
  • Secreted phospholipase A2 type IIA (sPLA2-IIA)

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Takada, Y., & Fujita, M. (2017). Secreted phospholipase A2 type IIA (sPLA2-IIA) activates integrins in an allosteric manner. In Advances in Experimental Medicine and Biology (Vol. 925, pp. 103-115). (Advances in Experimental Medicine and Biology; Vol. 925). Springer New York LLC. https://doi.org/10.1007/5584_2016_95

Secreted phospholipase A2 type IIA (sPLA2-IIA) activates integrins in an allosteric manner. / Takada, Yoshikazu; Fujita, Masaaki.

Advances in Experimental Medicine and Biology. Vol. 925 Springer New York LLC, 2017. p. 103-115 (Advances in Experimental Medicine and Biology; Vol. 925).

Research output: Chapter in Book/Report/Conference proceedingChapter

Takada, Y & Fujita, M 2017, Secreted phospholipase A2 type IIA (sPLA2-IIA) activates integrins in an allosteric manner. in Advances in Experimental Medicine and Biology. vol. 925, Advances in Experimental Medicine and Biology, vol. 925, Springer New York LLC, pp. 103-115. https://doi.org/10.1007/5584_2016_95
Takada Y, Fujita M. Secreted phospholipase A2 type IIA (sPLA2-IIA) activates integrins in an allosteric manner. In Advances in Experimental Medicine and Biology. Vol. 925. Springer New York LLC. 2017. p. 103-115. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/5584_2016_95
Takada, Yoshikazu ; Fujita, Masaaki. / Secreted phospholipase A2 type IIA (sPLA2-IIA) activates integrins in an allosteric manner. Advances in Experimental Medicine and Biology. Vol. 925 Springer New York LLC, 2017. pp. 103-115 (Advances in Experimental Medicine and Biology).
@inbook{61b2014fb4b24f5da952c9907f5ab931,
title = "Secreted phospholipase A2 type IIA (sPLA2-IIA) activates integrins in an allosteric manner",
abstract = "Secreted phospholipase A2 type IIA (sPLA2-IIA) is a well-established pro-inflammatory protein and has been a major target for drug discovery. However, the mechanism of its signaling action has not been fully understood. We previously found that sPLA2-IIA binds to integrins αvβ3 and α4β1 in human and that this interaction plays a role in sPLA2-IIA’s signaling action. Our recent studies found that sPLA2-IIA activates integrins in an allosteric manner through direct binding to a newly identified binding site of integrins (site 2), which is distinct from the classical RGD-binding site (site 1). The sPLA2-IIA-induced integrin activation may be related to the signaling action of sPLA2-IIA. Since sPLA2-IIA is present in normal human tears in addition to rheumatoid synovial fluid at high concentrations the sPLA2-IIA-mediated integrin activation on leukocytes may be involved in immune responses in normal and pathological conditions.",
keywords = "Allosteric site, Docking simulation, Integrin activation, Secreted phospholipase A2 type IIA (sPLA2-IIA)",
author = "Yoshikazu Takada and Masaaki Fujita",
year = "2017",
doi = "10.1007/5584_2016_95",
language = "English",
volume = "925",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "103--115",
booktitle = "Advances in Experimental Medicine and Biology",

}

TY - CHAP

T1 - Secreted phospholipase A2 type IIA (sPLA2-IIA) activates integrins in an allosteric manner

AU - Takada, Yoshikazu

AU - Fujita, Masaaki

PY - 2017

Y1 - 2017

N2 - Secreted phospholipase A2 type IIA (sPLA2-IIA) is a well-established pro-inflammatory protein and has been a major target for drug discovery. However, the mechanism of its signaling action has not been fully understood. We previously found that sPLA2-IIA binds to integrins αvβ3 and α4β1 in human and that this interaction plays a role in sPLA2-IIA’s signaling action. Our recent studies found that sPLA2-IIA activates integrins in an allosteric manner through direct binding to a newly identified binding site of integrins (site 2), which is distinct from the classical RGD-binding site (site 1). The sPLA2-IIA-induced integrin activation may be related to the signaling action of sPLA2-IIA. Since sPLA2-IIA is present in normal human tears in addition to rheumatoid synovial fluid at high concentrations the sPLA2-IIA-mediated integrin activation on leukocytes may be involved in immune responses in normal and pathological conditions.

AB - Secreted phospholipase A2 type IIA (sPLA2-IIA) is a well-established pro-inflammatory protein and has been a major target for drug discovery. However, the mechanism of its signaling action has not been fully understood. We previously found that sPLA2-IIA binds to integrins αvβ3 and α4β1 in human and that this interaction plays a role in sPLA2-IIA’s signaling action. Our recent studies found that sPLA2-IIA activates integrins in an allosteric manner through direct binding to a newly identified binding site of integrins (site 2), which is distinct from the classical RGD-binding site (site 1). The sPLA2-IIA-induced integrin activation may be related to the signaling action of sPLA2-IIA. Since sPLA2-IIA is present in normal human tears in addition to rheumatoid synovial fluid at high concentrations the sPLA2-IIA-mediated integrin activation on leukocytes may be involved in immune responses in normal and pathological conditions.

KW - Allosteric site

KW - Docking simulation

KW - Integrin activation

KW - Secreted phospholipase A2 type IIA (sPLA2-IIA)

UR - http://www.scopus.com/inward/record.url?scp=85019420975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019420975&partnerID=8YFLogxK

U2 - 10.1007/5584_2016_95

DO - 10.1007/5584_2016_95

M3 - Chapter

C2 - 27864802

AN - SCOPUS:85019420975

VL - 925

T3 - Advances in Experimental Medicine and Biology

SP - 103

EP - 115

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -